Engineered yeast probiotics containing a human P2Y2 purinergic receptor have been developed for the treatment of IBD by responding to physiological eATP levels and secreting the eATP-degrading enzyme apyrase218. This evidence concerns the gene P2RY2 and irritable bowel syndrome.